Confirmed Control Closed Transaction verified Antibody Drug ConjugatesBiotechOncologyTherapeutics
Tubulis acquired by Gilead Sciences
Gilead Sciences acquired Tubulis, a German therapeutics brand.
Transaction summary
- Target
- Tubulis
- Acquirer
- Gilead Sciences
- Seller
- -
- Announced
- -
- Geography
- Germany
- Tags
- Antibody Drug ConjugatesBiotechOncologyTherapeutics
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-13
- Latest update
- 2026-09-11
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- A comparable 100% enterprise value has not been established. Separately reported amounts are retained below.
Source summary
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Business Wire
ConfirmedBusiness Wire reported that Gilead Sciences completed its acquisition of Tubulis, strengthening Gilead's oncology portfolio.
Open source